Patent intelligence · US
US 6146653
Pharmaceutical preparation and a method for the treatment of diabetes
Pharmaceutical preparation and a method for the treatment of diabetes
Patent details — US 6146653
- Jurisdiction
- US
- Status
- expired
- Grant date
- Nov 14, 2000
- Expiration
- Nov 9, 2020
- Applicant
- Diataranz Limited
- Claims
- 14
- CPC classes
- A61K, A61K31/455
Quick answer
US 6146653 (Pharmaceutical preparation and a method for the treatment of diabetes) is held by Diataranz Limited. Status: expired. Granted Nov 14, 2000. Expires Nov 9, 2020 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Diataranz Limited
- Grant date
- Expiration
- Claims
- 14
- CPC classes
- A61K, A61K31/455
More from Diataranz Limited
Related pharmaceutical patents in our USPTO index.
-
US 12383572
Administration of an anti-activin-a compound to a subject
granted -
US 11925663
Methods of managing tumor flare in adoptive immunotherapy
granted -
US 11541070
Administration of an anti-activin-A compound to a subject
granted -
US 9968586
Mast cell stabilizers treatment for systemic disorders
granted -
US 9962363
Mast cell stabilizers treatment for systemic disorders
granted -
US 9707206
Mast cell stabilizers treatment for systemic disorders
granted -
US 9265749
Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
granted -
US 8501678
Variant activin receptor polypeptides and uses thereof
granted
Frequently asked questions
What is US patent 6146653?
US 6146653 (Pharmaceutical preparation and a method for the treatment of diabetes) is held by Diataranz Limited. Status: expired. Granted Nov 14, 2000. Expires Nov 9, 2020 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6146653?
Diataranz Limited is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 10 pharmaceutical patents for this assignee.
When does US 6146653 expire?
Our index shows an expiration date of Nov 9, 2020 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.